Phase II trial of Baker's antifol in patients with recurrent or inoperable head and neck cancer.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D005493:Folic Acid Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D014227:Triazines; C012071:triazinate